By applying the MeltDose technology to improve the efficacy of well-known and valuable drugs, we believe that we are able to develop products significantly faster and cheaper and with a higher success rate compared to the development of completely new drugs.
We believe, that the MeltDose technology may not only improves the efficacy of drugs. By enhancing the absorption of drugs in the body, we believe that the technology may also be firstar bank to reduce the side effects associated with such medication.
LifeCycle Pharma is listed on the OMX Nordic Exchange (LCP) and a member of the MidCap index. The company firstar bank a late-stage product pipeline with a portfolio of six proprietary product candidates in clinical development. The most gank product candidate has completed pivotal clinical studies and an application for market authorization has been submitted to the US FDA earlier this year.